

Product Name : Dilazep dihydrochloride

Synonyms : —

Cat No. : M26668

CAS Number : 20153-98-4

Molecular Formula : C₃₁H₄₆Cl₂N₂O₁₀

Formula Weight : 677.6

Chemical Name : —

Description : Dilazep dihydrochloride is an adenosine uptake inhibitor. Dilazep dihydrochloride also inhibits the ischemic damage, membrane transport of nucleosides and platelet aggregation. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. (In Vitro): Dilazep, NBI and Dipyridamole have been reported to inhibit the uptake of adenosine into different cells. The uptake mechanism has been studied extensively in vitro. In these compounds, Dilazep and NBI are almost 10 times more effective than Dipyridamole. Only Dilazep is water soluble and no solubility aiding organic solvent is needed for preparing an aqueous solution. (In Vivo): Dilazep inhibits the phospholipase activation in reperfused heart mitochondria and also inhibits the lipid peroxidation caused by cerebral ischemia and reperfusion. Dilazep may prevent ischemic cerebral injury due to an increase in cerebral blood flow and/or its protective effects on vascular endothelial cell membrane. After administration of Dilazep, even low doses (0.04-0.1 mg/kg/min) of exogenous adenosine significantly increases superior mesenteric arterial conductance (SMAC) and elevates arterial plasma adenosine concentration. The increased adenosine levels were highly correlated with the increased percentage of change of SMAC and values for R_{max} and EC₅₀ were 193.4% change of SMAC and 2.8 μM, respectively. Administration of bolus doses of 8-phenyltheophylline abolishes the ability of Dilazep to potentiate vasodilation. However, it did not affect isoproterenol-induced relaxation.

Pathway : Others

Target : Other Targets

Receptor : COX-2

Solubility : —

SMILES : Cl.Cl.COC1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1.Cho, Eui Hwan, et al.Pharmaceutical composition comprising rebamipide precursor for oral administration for preventing or treating immune disease and metabolic disease.WO2017138717A1.

FOR RESEARCH USE ONLY.NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.